Haemonetics Corporation
HAE
$69.38
$0.731.06%
NYSE
| 12/28/2024 | 09/28/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 0.88% | 2.78% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 0.88% | 2.78% | |||
| Cost of Revenue | -3.68% | 1.76% | |||
| Gross Profit | 4.56% | 3.62% | |||
| SG&A Expenses | 0.98% | 14.34% | |||
| Depreciation & Amortization | -0.28% | -1.66% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -1.87% | 6.54% | |||
| Operating Income | 14.59% | -12.63% | |||
| Income Before Tax | 11.66% | -4.30% | |||
| Income Tax Expenses | 14.26% | 30.37% | |||
| Earnings from Continuing Operations | 10.83% | -11.84% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 10.83% | -11.84% | |||
| EBIT | 14.59% | -12.63% | |||
| EBITDA | 9.47% | -8.68% | |||
| EPS Basic | 12.17% | -11.76% | |||
| Normalized Basic EPS | 13.80% | -30.48% | |||
| EPS Diluted | 12.12% | -10.81% | |||
| Normalized Diluted EPS | 13.76% | -30.10% | |||
| Average Basic Shares Outstanding | -1.20% | -0.09% | |||
| Average Diluted Shares Outstanding | -1.17% | -0.63% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||